These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31856269)

  • 1. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.
    Slomp A; Moesbergen LM; Gong JN; Cuenca M; von dem Borne PA; Sonneveld P; Huang DCS; Minnema MC; Peperzak V
    Blood Adv; 2019 Dec; 3(24):4202-4214. PubMed ID: 31856269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors.
    Juarez D; Buono R; Matulis SM; Gupta VA; Duong M; Yudiono J; Paul M; Mallya S; Diep G; Hsin P; Lu A; Suh SM; Dong VM; Roberts AW; Leverson JD; Jalaluddin M; Liu Z; Bueno OF; Boise LH; Fruman DA
    Cancer Res Commun; 2023 Dec; 3(12):2497-2509. PubMed ID: 37956312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells.
    Grundy M; Balakrishnan S; Fox M; Seedhouse CH; Russell NH
    Oncotarget; 2018 Dec; 9(102):37777-37789. PubMed ID: 30701031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.
    Chang H; Jiang N; Jiang H; Saha MN; Qi C; Xu W; Reece D
    Haematologica; 2010 Sep; 95(9):1542-7. PubMed ID: 20421271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
    Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
    J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of MicroRNAs With
    Weidle UH; Nopora A
    Cancer Genomics Proteomics; 2020; 17(4):321-334. PubMed ID: 32576578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
    Johnson TS; Sudha P; Liu E; Becker N; Robertson S; Blaney P; Morgan G; Chopra VS; Dos Santos C; Nixon M; Huang K; Suvannasankha A; Zaid MA; Abonour R; Walker BA
    Nat Commun; 2024 May; 15(1):4144. PubMed ID: 38755140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of a Myeloid cell leukemia-1 (Mcl-1) inhibitor bound to drug site 3 of Human Serum Albumin.
    Zhao B; Sensintaffar J; Bian Z; Belmar J; Lee T; Olejniczak ET; Fesik SW
    Bioorg Med Chem; 2017 Jun; 25(12):3087-3092. PubMed ID: 28428041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated interferon response from DNA damage in multiple myeloma cells contributes to the chemotherapeutic effects of anthracyclines.
    Li J; Jia Z; Wang R; Xiao B; Cai Y; Zhu T; Wang W; Zhang X; Fan S; Fan X; Han W; Lu X
    Front Oncol; 2024; 14():1357996. PubMed ID: 38800411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The numerous facets of 1q21
    Liu N; Xie Z; Li H; Wang L
    Oncol Lett; 2024 Jun; 27(6):258. PubMed ID: 38646497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors.
    Sklavenitis-Pistofidis R; Lightbody ED; Reidy M; Tsuji J; Aranha MP; Heilpern-Mallory D; Huynh D; Chong SJF; Hackett L; Haradhvala NJ; Wu T; Su NK; Berrios B; Alberge JB; Dutta A; Davids MS; Papaioannou M; Getz G; Ghobrial IM; Manier S
    bioRxiv; 2023 Aug; ():. PubMed ID: 37577538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting MCL-1 in hematologic malignancies: Rationale and progress.
    Wei AH; Roberts AW; Spencer A; Rosenberg AS; Siegel D; Walter RB; Caenepeel S; Hughes P; McIver Z; Mezzi K; Morrow PK; Stein A
    Blood Rev; 2020 Nov; 44():100672. PubMed ID: 32204955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma.
    Hanamura I
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.
    Alfarra H; Weir J; Grieve S; Reiman T
    Front Immunol; 2020; 11():575609. PubMed ID: 33304346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities.
    Abdallah N; Greipp P; Kapoor P; Gertz MA; Dispenzieri A; Baughn LB; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Go RS; Hwa YL; Fonder A; Hobbs M; Lin Y; Leung N; Kourelis T; Warsame R; Siddiqui M; Lust J; Kyle RA; Bergsagel L; Ketterling R; Rajkumar SV; Kumar SK
    Blood Adv; 2020 Aug; 4(15):3509-3519. PubMed ID: 32750129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma.
    Misiewicz-Krzeminska I; de Ramón C; Corchete LA; Krzeminski P; Rojas EA; Isidro I; García-Sanz R; Martínez-López J; Oriol A; Bladé J; Lahuerta JJ; San Miguel J; Rosiñol L; Mateos MV; Gutiérrez NC
    Blood Adv; 2020 Dec; 4(23):6023-6033. PubMed ID: 33284947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk and Response-Adapted Treatment in Multiple Myeloma.
    Cazaubiel T; Mulas O; Montes L; Schavgoulidze A; Avet-Loiseau H; Corre J; Perrot A
    Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33255368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma.
    Mukherjee N; Amato CM; Skees J; Todd KJ; Lambert KA; Robinson WA; Van Gulick R; Weight RM; Dart CR; Tobin RP; McCarter MD; Fujita M; Norris DA; Shellman YG
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32764384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and Clinical Sgnificance of IL-6, IL-6R and MCL-1 in Patients with Multiple Myeloma].
    Wang BW; Sun H; Chen X; Li XL; Liu HT; Chai T
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):553-557. PubMed ID: 32319395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis, Biology, and Targeting of
    Flynt E; Bisht K; Sridharan V; Ortiz M; Towfic F; Thakurta A
    Cells; 2020 Jan; 9(2):. PubMed ID: 31991614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.